You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Biogen Idec reports 4Q revenue rise of 7 percent

Biogen Idec Inc., a Weston company known for its multiple sclerosis drugs such as Avonex and Tysabri, said Monday that its fourth-quarter revenues rose 7 percent on a year-to-year basis to $1.4 billion.

Fourth-quarter 2012 GAAP diluted earnings per share were $1.23, an increase of 1 percent over the fourth quarter of 2011. GAAP net income attributable to Biogen Idec for the quarter was $292 million, a decrease of 3 percent from the fourth quarter of 2011.

Continue reading below

In a press release, the company said it corrected its accounting for taxes on capitalized interest at its Denmark facility. The error accumulated over several years and increased tax expense in the quarter by $29 million. GAAP and non-GAAP net income attributable to Biogen Idec and diluted EPS include the impact of our correction. This unfavorably impacted both GAAP and non-GAAP fourth-quarter 2012 diluted EPS by 12 cents.

Total revenues in 2012 increased 9 percent to $5.5 billion year-over-year.

George Scangos. Reuters file photo by Mike Segar.

On a reported basis, full year 2012 GAAP diluted EPS were $5.76, an increase of 14 percent versus 2011. GAAP net income attributable to Biogen Idec for the year was $1.4 billion, an increase of 12 percent versus 2011, the company said.

“We recorded another solid year of revenue growth and profitability, all while advancing our late-stage pipeline and investing in upcoming product launches,” George A. Scangos, Biogen Idec’s chief executive, said in a statement. “We are poised to begin what we expect will be a remarkable period of growth, driven by our promising compounds including TECFIDERA and Peginterferon beta-1a for MS, and both Factor VIII and Factor IX for hemophilia. We appreciate the excitement that MS and hemophilia patients have expressed to us about these candidates, and our teams are well prepared to support the launches. We expect MS and hemophilia patients will benefit from these important new products for years to come.”

Biogen Idec also announced its full year 2013 financial guidance. Revenue growth is expected to be approximately 10 percent.

Non-GAAP diluted EPS is expected to be between $7.15 and $7.25, and GAAP diluted EPS is expected to be between $6.45 and $6.55.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of